Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings

Lisa Vermunt*, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrie, Julien Delrieu, Karine Fauria, Gema Huesa Rodriguez, Silvia Ingala, Natalie Jenkins, Jose Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D. Prins, Alina Solomon, Brian D. Tom, Henrik Zetterberg, Marissa ZwanCraig W. Ritchie, Philip Scheltens, Gerald Luscan, Anthony J. Brookes, Pieter Jelle Visser, IMI-EPAD collaborators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number8
Number of pages10
JournalAlzheimer's Research & Therapy
Volume12
Issue number1
DOIs
Publication statusPublished - 6 Jan 2020

Keywords

  • Prescreening
  • Amyloid
  • Secondary prevention trials
  • Registries
  • Recruitment
  • Engagement
  • Trial-ready cohort
  • CLINICAL-TRIALS
  • DISEASE
  • ASSOCIATION
  • PREVALENCE
  • RETENTION
  • GENOTYPE

Cite this